Circassia Puts Aside R&D, Aims To Grow Commercial Platform
UK biotech Circassia puts Phase III cat allergy vaccine failure behind it and intends to move forward with building its commercial platform, and sales, in the respiratory sector.
You may also be interested in...
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.
After a promising research program failed to deliver, London-listed Circassia changed from being an R&D-based allergy company to one focused on commercial respiratory therapies. Rapid decision-making averted a crisis and earned the company a US deal and equity partnership with AstraZeneca. As an exercise in Plan B readiness, it's surely up there with the best.
AstraZeneca has released positive top-line data from a new Phase III study of the LAMA/LABA combination, Duaklir, in COPD that could lead to a US NDA filing in 2018, and the start of US marketing by partner Circassia.